Search results for "Antibodies monoclonal"

showing 10 items of 11 documents

Immunszintigraphie und -therapie

2008

Antibodies monoclonalbusiness.industrymedicine.medical_treatmentmedicineCancer researchGeneral MedicineImmunotherapybusinessImmunoscintigraphyDMW - Deutsche Medizinische Wochenschrift
researchProduct

The Cell Surface of <i>Candida albicans</i> during Morphogenesis

2000

Cell wallFungal proteinmedicine.anatomical_structureAntibodies monoclonalCellmedicineMorphogenesisBiologyCandida albicansbiology.organism_classificationCell biologyMicrobiology
researchProduct

Occult Hepatitis B and Infliximab-induced HBV Reactivation

2007

Crohn diseasebusiness.industryCarrier stateGastroenterologyHbv reactivationVirus ActivationHepatitis Bmedicine.diseaseVirologyOccultInfliximabAntibodies monoclonalmedicineImmunology and Allergybusinessmedicine.drugInflammatory Bowel Diseases
researchProduct

Daratumumab for the Treatment of Multiple Myeloma

2018

This mini-review will summarize the present state of development of the CD38 antibody daratumumab for the treatment of multiple myeloma.

Cytotoxicity Immunologic0301 basic medicineOncologylcsh:Immunologic diseases. Allergymedicine.medical_specialtyAdenosineTreatment outcomeImmunologyDrug Evaluation PreclinicalComplementAntineoplastic AgentsMyelomaimmunomodulationImmunomodulation03 medical and health sciences0302 clinical medicineAntibodies monoclonalimmune system diseasesInternal medicineDaratumumabhemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansImmunology and AllergycomplementMultiple myelomaNeonatal Fc-receptorsClinical Trials as Topicbusiness.industryAntibody-Dependent Cell CytotoxicityAntibodies MonoclonalDaratumumabmedicine.diseasedaratumumabTrogocytosis3. Good healthTreatment Outcome030104 developmental biologymyelomaadenosine030220 oncology & carcinogenesisAntibody-dependent cell cytotoxicityMultiple Myelomabusinesslcsh:RC581-607CD38Frontiers in Immunology
researchProduct

Immunbiologie der Transplantatabstoßung und deren pharmakologische Beeinflussung

2008

Graft rejectionAntibodies monoclonalbusiness.industryImmunologymedicineGeneral MedicineHuman leukocyte antigenmedicine.diseasebusinessANTIGENS CDTransplant rejectionDMW - Deutsche Medizinische Wochenschrift
researchProduct

Letter: switching from one to another anti-tumour necrosis factor alpha agent, and the risks of an overlap of exposure

2016

Hepatologybiologybusiness.industryImmunoglobulin Fab FragmentsGastroenterologyInflammatory Bowel DiseasesToxicology03 medical and health sciences0302 clinical medicineAntibodies monoclonal030220 oncology & carcinogenesisMonoclonalbiology.proteinCancer researchMedicine030211 gastroenterology & hepatologyPharmacology (medical)Tumor necrosis factor alphaAnti-tumour necrosis factor alpha agentAntibodybusinessAlimentary Pharmacology & Therapeutics
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

El grosor macular podría ser un predictor de la probabilidad de recidiva de los edemas maculares por oclusiones venosas de la retina tratados mediant…

2009

Ophthalmologymedicine.medical_specialtyMacula LuteaAntibodies monoclonalbusiness.industryOphthalmologyMonoclonalmedicineRanibizumabbusinessmedicine.diseaseMacular edemamedicine.drug
researchProduct

Quantitative characterization of antigens using monoclonal antibody reactivities

1993

A multipurpose program that empirically relates antigenic reactivities with monoclonal antibodies (MAbs) to genetic distances is presented. The program uses a set of known genetic pairwise distances to weigh each MAb depending on its capacity to define groups of taxonomically related antigens. This allows highly accurate identification and classification of unknown antigens. Also, the weights obtained constitute a quantitative measure of epitope conservation and can be used for improved vaccine design. © 1993 Oxford University Press.

Statistics and ProbabilityAnticorps monoclonalmedicine.drug_classComputational biologyMonoclonal antibodyBiochemistryEpitopeEpitopesAntigenMicrocomputersAntibodies monoclonalmedicineAntigensMolecular BiologyMathematicsbiologyAntibodies MonoclonalVirologyComputer Science ApplicationsQuantitative measureComputational MathematicsComputational Theory and Mathematicsbiology.proteinAntibodyAlgorithmsSoftware
researchProduct

M22 based (manual) ELISA for TSH-receptor antibody (TRAb) measurement is more sensitive than 2nd generation TRAb assays

2009

biologybusiness.industryBiochemistry (medical)Clinical BiochemistryTrabGeneral MedicineBiochemistryAntibodies monoclonalImmunologyTSH receptor antibodybiology.proteinMedicineAntibodybusinessClinica Chimica Acta
researchProduct